Time filter

Source Type

Seoul, South Korea

Lee W.K.,Hallym University | Lee S.H.,Hallym University | Cho S.T.,Kangnam Sacred Heart Hospital | Lee Y.S.,Hangang Sacred Heart Hospital | And 5 more authors.
Journal of Sexual Medicine | Year: 2013

Introduction: There is partial evidence to support the use of phophodiesterase-5 inhibitor (PDE5-I) for the treatment of premature ejaculation (PE). Aim: We compared on-demand dosing of dapoxetine alone and combined with mirodenafil in subjects with lifelong PE and without erectile dysfunction (ED). Methods: Our prospective, randomized, double-blind, placebo-controlled, multicenter trial enrolled 118 subjects with lifelong PE without ED. PE was diagnosed using Diagnostic andStatisticalManual ofMentalDisorders, fourth edition, text revision. Patients were divided into two groups: dapoxetine 30mg plus placebo (group A, n=56) and dapoxetine 30mg plus mirodenafil 50mg (group B, n=62). Main Outcome Measures: During 12 weeks, intravaginal ejaculatory latency time (IELT) and the time from foreplay to beginning intercourse (FTIT) with a stopwatch, and Premature Ejaculation Profile (PEP) were measured. Overall sexual act time (OSAT; sum of FTIT and IELT) was calculated. Any treatment-emergent adverse events (TEAEs) were also recorded. Results: Over 12 weeks, IELT, OSAT, and PEP index score significantly improved in group B compared with group A (increased geometric mean IELT in group A and B=3.6 and 6.1 minutes, P=0.026; increased geometric mean OSAT in group A and B=5.5 and 9.9 minutes, P=0.012; increased median PEP index score in group A and B=1.0 and 1.3, P=0.046). However, there was no significant difference between two groups with respect to improvement of FTIT (P=0.147). TEAEs did not differ between groups (all P>0.05), and there was no serious adverse event in any subjects. Conclusions: Low dose of dapoxetine combined with mirodenafil showed better results in terms of IELT, OSAT, and PEP index score, and similar TEAEs, compared with that of dapoxetine only. Our results support the suggestion that the PDE5-Is have a potential role in the treatment of PE without ED. © 2013 International Society for Sexual Medicine. Source

Pan C.,Chinese PLA General Hospital | Yoo H.J.,Hangang Sacred Heart Hospital | Ho L.-T.,Taipei Veterans General Hospital | Ho L.-T.,National Yang Ming University
Journal of Obesity | Year: 2011

Rimonabant, a selective cannabinoid-1 (CB1) receptor antagonist, has been shown to reduce weight and enhance improvements in cardiometabolic risk parameters in Western populations. This study assessed these effects of rimonabant in Asian population. A total of 643 patients (BMI 25 kg / m 2 or greater without diabetes) from China, Republic of Korea, and Taiwan were prescribed a hypocaloric diet (600 kcal/day deficit) and randomized to rimonabant 20 mg (n = 318) or placebo (n = 325) for 9months. The primary efficacy variable was weight change from baseline after 9 months of treatment. Results showed that rimonabant group lost more weight than placebo, (LSM ± SEM of -4.7 ± 0.3 kg vs. -1.7 ± 0.3 kg, P <.0001). The 5% and 10% responders were 2 or 3 folds more in the rimonabant group (53.0% vs. 20.0% and 21.5% vs. 5.7%, resp.) (P <.0001). Rimonabant also significantly increased HDL-cholesterol, decreased triglycerides and waist circumference,by 7.1%, 10.6%, and 2.8 cm, respectively (P <.0001). This study confirmed the comparable efficacy and safety profile of rimonabant in Asian population to Caucasians. Owing to the recent suspension of all the CB1 antagonists off the pharmaceutical market for weight reduction in Europe and USA, a perspective in drug discovery for intervening peripheral CB1 receptor in the management of obesity is discussed. © 2011 Changyu Pan et al. Source

Lim S.,Seoul National University | Kang S.M.,Seoul National University | Lee H.J.,Seoul National University | Yoon J.W.,Seoul National University | And 7 more authors.
Diabetes Care | Year: 2011

OBJECTIVE - To improve quality and efficiency of care for elderly patients with type 2 diabetes, we introduced elderly-friendly strategies to the clinical decision support system (CDSS)-based ubiquitous healthcare (u-healthcare) service, which is an individualized health management system using advanced medical information technology. RESEARCH DESIGN AND METHODS - We conducted a 6-month randomized, controlled clinical trial involving 144 patients aged >60 years. Participants were randomly assigned to receive routine care (control, n = 48), to the self-monitored blood glucose (SMBG, n = 47) group, or to the u-healthcare group (n = 49). The primary end point was the proportion of patients achieving A1C <7% without hypoglycemia at 6 months. U-healthcare system refers to an individualized medical service in which medical instructions are given through the patient's mobile phone. Patients receive a glucometer with a public switched telephone network-connected cradle that automatically transfers test results to a hospital-based server.Once the data are transferred to the server, an automated system, the CDSS rule engine, generates and sends patient-specific messages by mobile phone. RESULTS - After 6 months of follow-up, the mean A1C level was significantly decreased from 7.8 ±1.3% to 7.4 ± 1.0% (P< 0.001) in the u-healthcare group and from 7.9 ±1.0% to 7.7 ± 1.0%(P = 0.020) in the SMBG group, compared with 7.9±0.8% to 7.861.0% (P=0.274) in the control group. The proportion of patients with A1C <7% without hypoglycemia was 30.6% in the u-healthcare group, 23.4% in the SMBG group (23.4%), and 14.0%in the control group (P< 0.05). CONCLUSIONS - The CDSS-based u-healthcare service achieved better glycemic control with less hypoglycemia than SMBG and routine care and may provide effective and safe diabetes management in the elderly diabetic patients. © 2011 by the American Diabetes Association. Source

Lim J.W.,Chuncheon Sacred Heart Hospital | Han J.R.,Hangang Sacred Heart Hospital
Clinical and Experimental Ophthalmology | Year: 2011

Background: To determine the aqueous humour levels of vascular endothelial growth factor (VEGF) and erythropoietin (EPO) in eyes with diabetic macular oedema before and after intravitreal EPO injection. Design: Prospective interventional case series. Participants: Eleven eyes of 11 patients with diabetic macular oedema, and 10 eyes of 10 patients with cataract surgery as controls. Main Outcomes Measures: EPO and VEGF levels in aqueous humour before and after intravitreal EPO injection in patients and compared with controls. Methods: Eyes with diabetic macular oedema received an intravitreal injection of EPO (1000IU/0.05mL), followed by various intraocular procedures at different intervals (1-54days) after injection. An aqueous humour sample was obtained and aqueous humour levels of EPO and VEGF were measured using enzyme-linked immunosorbent assay. Results: The aqueous levels of EPO and VEGF were significantly elevated in diabetic macular oedema eyes compared to control eyes (P<0.05). EPO levels in patients correlated with VEGF levels (r=0.816, P=0.002) and central macular thickness at baseline (r=0.618, P=0.043). After intravitreal EPO injection, aqueous EPO levels were significantly elevated, whereas aqueous VEGF levels were varied according to the time interval since injection. Visual acuity and central macular thickness were not different after injection, compared to before injection. Aqueous EPO levels did not correlate with serum EPO levels(r=0.299, P=0.371). Conclusions: EPO is locally expressed and is correlated with VEGF in eyes with diabetic macular oedema. The role of EPO and the effect of intravitreal EPO in patients with diabetic macular oedema need to be further defined. © 2011 The Authors. Clinical and Experimental Ophthalmology © 2011 Royal Australian and New Zealand College of Ophthalmologists. Source

Park B.-Y.,Hallym University | Lee B.-C.,Hangang Sacred Heart Hospital | Jung K.H.,Hanyang University | Jung M.H.,Hangang Sacred Heart Hospital | And 3 more authors.
Psychiatry Investigation | Year: 2011

Objective: Psychiatric disorders such as depression, anxiety and alcohol dependence are associated with serotonin metabolism. We assessed the methylation level of the serotonin transporter (5-HTT) promoter region in control and alcohol dependent patients. Method: Twenty seven male patients who met the Diagnostic and Statistical Manual of Mental Disorder IV (DSM-IV) criteria for alcohol dependence were compared with fifteen controls. Polymerase chain reaction (PCR) assays of bisulfate-modified DNA were designed to amplify a part of the CpG island in the 5HTT gene. Pyrosequencing was performed and the methylation level at seven CpG island sites was measured. Result: We found no differences in the methylation patterns of the serotonin transporter linked promoter region (5-HTTLPR) between alcohol-dependent and control subjects. Conclusion: Our negative finding may be because 5-HTT epigenetic variation may not affect the expression for 5-HTT or there may be other methylation site critical for its expression. To find out more conclusive result, repeating the study in more methylation sites with a larger number of samples in a well-controlled setting is needed. © 2011 Korean Neuropsychiatric Association. Source

Discover hidden collaborations